Millendo Therapeutics initiates first-in-human clinical trial of MLE-301
“We are pleased to advance MLE-301 into clinical development, prioritizing our resources on this valuable asset and leveraging Millendo’s expertise in the NK3R category,” said Julia C. Owens,